Health Condition 1: null- Type 2 Diabetes Mellitus patients
Conditions
Interventions
Intervention1: Rosuvastatin: Rosuvastatin 20mg/day given once daily, orally for 3 months
Control Intervention1: Rosuvastatin: Rsouvastatin 20mg/day given once daily, orally for 3 months.
Control Inter
Sponsors
Sri Venkateswara Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: Newly diagnosed male patients with T2DM aged between 40-70 years as per the revised ADA criteria (37):i.e i) Fasting plasma glucose =126mg/dL (7.0mmol/L) ii) 2 hour plasma glucose =200mg/dL (11.1mmol/L) iii) Glycosylated hemoglobin (HbA1c) >6.5% (48 mmol/mol) Patients with T2DM on oral antidiabetic treatment and with LDL levels > 75 mg/dl will be included.
Exclusion criteria
Exclusion criteria: Female patients with type 2 Diabetes mellitus Patients with other forms of Diabetes (T1DM, Gestational diabetes mellitus) Those on insulin therapy Thyroid disorders not on treatment Those on pioglitazone Liver and kidney diseases Other inflammatory diseases Acute illness Malignancy Alcoholics Current smoking On cholesterol lowering drugs Individuals who are not willing to participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determine the anti-atherogenic effects of rosuvastatin namely its anti-oxidant and anti-inflammatory effects in patients with type 2 diabetes mellitusTimepoint: 2 | — |
Secondary
| Measure | Time frame |
|---|---|
| Determine the lipid lowering capacity of rosuvastatin by assessment of lipid profile in patients with T2DM before and after 12 weeks of Rosuvastatin treatmentTimepoint: 2 | — |
Countries
India
Contacts
Public ContactS Naresh
Sri Venkateswara Institute of Medical Sciences
Outcome results
None listed